<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430013</url>
  </required_header>
  <id_info>
    <org_study_id>2367240</org_study_id>
    <nct_id>NCT01430013</nct_id>
  </id_info>
  <brief_title>Trial of Endostar Combined With CHOPT for T Cell Lymphoma</brief_title>
  <official_title>Phase II Trial of Endostar Combined With CHOPT for T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simcere Pharmaceutical Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Endostar combined with CHOPT in the treatment of T
      cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy including overall response rate, progression free survival and overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>According to International Workshop Criteria, the number of participants with complete remission, partial remission and stable disease as a measure of efficacy.progressive free survival and overall survival of the participants are the second measure of efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of Endostar combined with CHOPT chemotherapy</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants with adverse events as a measure of safety</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Endostar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHOPT chemotherapy plus Endostar</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar and CHOPT</intervention_name>
    <description>Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone</description>
    <arm_group_label>Endostar</arm_group_label>
    <other_name>Endostatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female aged 18 to 70 years old.

          2. Diagnosis of T cell lymphoma according to WHO Classification, without antitumor
             therapy

          3. At least 1 measurable tumor mass (greater than 1.5cm in the longest dimension and
             greater than 1.0 in the short axis)

          4. Eastern Cooperative Oncology Group status 0-2

          5. White blood cell≥4.0×109cells/L; Absolute neutrophil count (ANC) ≥1.5×109cells /L;
             Platelets≥100×109cells/L

          6. Alanine transaminase (ALT) ≤2×upper limit of normal(ULN); Aspartate transaminase (AST)
             ≤2×ULN; Total Bilirubin≤1.5×ULN; Creatinine in normal range

        Exclusion Criteria:

          1. No active central nervous system lymphoma or brain tumor

          2. Suppurative inflammation,Chronic infection

          3. Severe heart disease, conclusion: congestive heart failure; uncontrolled cardiac
             arrhythmia; myocardial infarction; refractory hypertension

          4. psychiatric history

          5. Primary cutaneous T cell lymphoma

          6. Pregnant or lactating women

          7. Concurrent treatment with another investigational agent

          8. Accept radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huaqing wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institue and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

